References
- Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011;14:417-28
- Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health 2011;14:429-37
- Cooper NJ, Sutton AJ, Morris D, et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Stat Med 2009;28:1861-81
- Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:447-59
- Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 1997;16:2741-58
- Turner RM, Omar RZ, Yang M, et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000;19:3417-32
- Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials. A method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28:935-45
- Signorovitch JE, Sickirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 2012;15:940-7
- National Institute for Health and Care Excellence. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. London 2015. Available at: https://www.nice.org.uk/guidance/ta331. Last accessed: 19 October 2015
- Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015;62:1047-55
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatol 1996;24:289
- Ishak K, Baptista A, Bianchi L, et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995;24:289-93
- Shiha G, Zalata K. Ishak versus METAVIR: Terminology, convertibility and correlation with laboratory changes in chronic hepatitis C. In: Takahashi H (ed.) Liver Biopsy. InTech. Available at: http://www.intechopen.com/books/liver-biopsy/ishak-versus-metavirterminology-convertibility-and-correlation-with-laboratory-changes-in-chronic-h. Last accessed: 19 October 2015
- Varghese R, Al-Khaldi J, Asker H, et al. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009;56:218-22
- Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterol 2010;138:108-15
- El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009;81:1576-83
- Rossignol J, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterol 2009;136:856-62
- Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2011;31:401-11
- Jacobson I, Dore G, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: the phase 3, randomised, double-blind, placebo-controlled QUEST-1 trial. Lancet 2014;384:403-13
- Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon α-2a or α-2b/ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naive patients: QUEST-2, a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2014;384:414-26
- Taieb V, Pacou M, Ho S, et al. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-alpha and ribavirin in patients infected with genotype 1 hepatitis C virus. J Med Econ 2015;18:787-96